Synthesis, docking, pharmacokinetic prediction, and acetylcholinesterase inhibitory evaluation of N-(2-(piperidine-1-yl)ethyl)benzamide derivatives as potential anti-Alzheimer agents

Ahmad Mohammadi-Farani , Farzaneh Moradi, Amin Hosseini, Alireza Aliabadi

Abstract


Background and purpose: Alzheimer’s disease is the most common form of dementia and the sixth most common cause of death in the US according to the Alzheimer’s Association. As regards, to date, no effective treatments are available because of the multifactorial nature of the disease, therefore, a large body of recent research has been allocated to the design and development of multi-target-directed ligands that can become effective drug candidates.

Experimental approach: A novel series of benzamide derivatives (5a-5l) containing piperidine core were synthesized in the current work. After identification of the chemical structures of the members of this series using 1H NMR, IR, and MS spectra, their anti-acetylcholinesterase activity was assessed by the Ellman᾽s test. Docking studies were also performed to investigate the binding mode and determine the interacting amino acids with the corresponding ligands. Finally, the pharmacokinetic (ADME parameters) of the most potent derivative (5d) was predicted and compared with donepezil.     

Findings/Results: Compound 5d possessing the fluorine atom substitution at position ortho was the most active compound in these series (IC50 = 13 ± 2.1 nM). This compound demonstrated superior activity than the reference drug donepezil (IC50 = 0.6 ± 0.05 µM). Molecular docking showed a significant hydrogen bonding of the carbonyl group of compounds 5d with tyrosine 121 into the active site of acetylcholinesterase. Fortunately, this compound showed better promising ADME properties than donepezil.

Conclusion and implication: The benzamide derivatives introduced in this paper could be proposed as potential anti-acetylcholinesterase.

 

 


Keywords


Acetylcholinesterase; Alzheimer’s disease; Piperidine; Synthesis.

Full Text:

PDF

References


Bagheri M, Joghataei MT, Mohseni S, Roghani M. Genistein ameliorates learning and memory deficits in amyloid β (1-40) rat model of Alzheimer’s disease. Neurobiol Learn Mem. 2011;1;95(3):270-276.DOI: 10.1016/j.nlm.2010.12.001.

Patel V, Flisher AJ, Hetrick S, McGorry P. Mental health of young people: a global public-health challenge. Lancet 2007;14;369(9569):1302-1313.DOI: 10.1016/S0140-6736(07)60368-7.

Batty GD, Deary IJ, Gottfredson LS. Premorbid (early life) IQ and later mortality risk: systematic review. Ann Epidemiol. 2007;17(4):278-288.DOI: 10.1016/j.annepidem.2006.07.010.

Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382(9904):1575-1586.DOI: 10.1016/S0140-6736(13)61611-6.

Gallagher M, Pelleymounter MA. Spatial learning deficits in old rats: a model for memory decline in the aged. Neurobiol Aging. 1988;9(5-6):549-556.DOI: 10.1016/s0197-4580(88)80112-x.

Shi DH, Huang W, Li C, Wang LT, Wang SF. Synthesis, biological evaluation and molecular modeling of aloe-emodin derivatives as new acetylcholinesterase inhibitors. Bioorg Med Chem. 2013;21(5):1064-1073.DOI: 10.1016/j.bmc.2013.01.015.

Wang CH, Wang LS, Zhu N. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer’s disease therapies: an updated umbrella review of systematic reviews and meta-analyses. Eur Rev Med Pharmacol Sci. 2016;20(22):4801-4817.PMID: 27906438.

Bent-Ennakhil N, Coste F, Xie L, Aigbogun MS, Wang Y, Kariburyo F, et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients. Neurol Ther. 2017;6(1):131-144.DOI: 10.1007/s40120-017-0067-7.

Sun G, Wang J, Guo X, Lei M, Zhang Y, Wang X, et al. Design, synthesis and biological evaluation of LX2343 derivatives as neuroprotective agents for the treatment of Alzheimer's disease. Eur J Med Chem. 2018;145:622-633.DOI: 10.1016/j.ejmech.2017.12.080.

Y.X. Xu, H. Wang, X.K. Li, S.N. Dong, W.W. Liu, Q. Gong, et al. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease, Eur J Med Chem. 143 (2018) 33-47.DOI: 10.1016/j.ejmech.2017.08.025.

Joubert J, Foka GB, Repsold BP, Oliver DW, Kapp E, Malan SF. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem. 2017;125:853-864.DOI: 10.1016/j.ejmech.2016.09.041.

Regier DA, Farmer ME, Rae DS, Myers JK, Kramer MR, Robins LN, et al. One‐month prevalence of mental disorders in the United States and sociodemographic characteristics: the epidemiologic catchment area study. Acta Psychiatr Scand. 1993;88(1):35-47.DOI: 10.1111/j.1600-0447.1993.tb03411.x.

Chiriano G. Computer-and synthesis-based approaches towards the discovery of novel BACE-1 inhibitors as potential anti-Alzheimer’s drugs. 2011. pp.18-20.

Wong DM, Greenblatt HM, Dvir H, Carlier PR, Han YF, Pang YP, et al. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. J Am Chem Soc. 2003;125(2):363-373.DOI: 10.1021/ja021111w.

Aliabadi A, Mohammadi-Farani A, Bistouni JR. Synthesis and acetylcholinesterase inhibitory assessment of benzamide derivatives incorporated piperazine moiety as potential anti-Alzheimer agents. J Pharm Sci Res. 2017;9(9):1598-1603.

Pourshojaei Y, Abiri A, Eskandari K, Haghighijoo Z, Edraki N, Asadipour A. Phenoxyethyl piperidine/morpholine derivatives as PAS and CAS inhibitors of cholinesterases: insights for future drug design. Sci. Rep. 2019;27;9(1):19855,1-19.DOI: 10.1038/s41598-019-56463-2.

Korabecny J, Spilovska K, Mezeiova E, Benek O, Juza R, Kaping D, et al. A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer’s disease. Curr. Med. Chem. 2019;26(30):5625-5648.DOI: 10.2174/0929867325666180517094023.

Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem. 2000;7(3):303-339.DOI: 10.2174/0929867003375191.

Mehrabi F, Pourshojaei Y, Moradi A, Sharifzadeh M, Khosravani L, Sabourian R, et al. Design, synthesis, molecular modeling and anticholinesterase activity of benzylidene-benzofuran-3-ones containing cyclic amine side chain. Future Med Chem. 2017;9(7):659-671.DOI: 10.4155/fmc-2016-0237.

Shamsimeymandi R, Pourshojaei Y, Eskandari K, Mohammadi‐Khanaposhtani M, Abiri A, Khodadadi A, et al. Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti‐Alzheimer's agents. Arch Pharm. 2019;352(7):1800352,1-12.DOI: 10.1002/ardp.201800352.

Abolhasani F, Pourshojaei Y, Mohammadi F, Esmaeilpour K, Asadipour A, Ilaghi M, et al. Exploring the potential of a novel phenoxyethyl piperidine derivative with cholinesterase inhibitory properties as a treatment for dementia: Insights from STZ animal model of dementia. Neurosci Lett. 2023;27;810:137332.DOI: 10.1016/j.neulet.2023.137332.

McHardy SF, Wang HY, McCowen SV, Valdez MC. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015). Expert Opin Ther Pat. 2017;27(4):455-476.DOI: 10.1080/13543776.2017.1272571.

Cooper EL, Ma MJ. Alzheimer disease: clues from traditional and complementary medicine. J Tradit Complement Med. 2017;7(4):380-385.DOI: 10.1016/j.jtcme.2016.12.003.

Houghton PJ, Howes MJ. Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease. Neurosignals. 2005;14(1-2):6-22.DOI: 10.1159/000085382.

Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59(4-5):290-294.DOI: 10.1016/j.neuropharm.2010.04.005.

Mohammadi-Farani A, Nazari S, Mohammadi M, Navid SJ, Hosseini A, Aliabadi A. Novel acetylcholinesterase inhibitors: synthesis, docking and inhibitory activity evaluation of 4-benzamido-N-(1-benzylpiperidin-4-yl) benzamide derivatives. Results Chem. 2024;7:101273,1-8.DOI: 10.1016/j.rechem.2023.101273.

Mohammadi-Farani A, Takesh M, Mohammadi M, Hosseini A, Aliabadi A, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory evaluation of 1, 3, 4-thiadiazole derivatives as potential anti-alzheimer agents. Pharm Sci. 2024;30(3):1-10.DOI: 10.34172/PS.2024.7.

Yanez M, Vina D. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. Curr Top Med Chem. 2013;13(14):1692-1706.DOI: 10.2174/15680266113139990120.

Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D, at al. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer’s disease: the design of donecopride. J Med Chem. 2015;58(7):3172-3187.DOI: 10.1021/acs.jmedchem.5b00115.

Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl) ethyl) isoindoline-1, 3-dione derivatives with potential anti-Alzheimer effects. Daru. 2013;21(1):47,1-9.DOI: 10.1186/2008-2231-21-47.

Aliabadi A, Shamsa F, Ostad SN, Emami S, Shafiee A, Davoodi J, et al. Synthesis and biological evaluation of 2-phenylthiazole-4-carboxamide derivatives as anticancer agents. Eur J Med Chem. 2010;45(11):5384-5389.DOI: 10.1016/j.ejmech.2010.08.063.

Rahmani Khajouei M, Mohammadi-Farani A, Moradi A, Aliabadi A. Synthesis and evaluation of anticonvulsant activity of (Z)-4-(2-oxoindolin-3-ylideneamino)-N-phenylbenzamide derivatives in mice. Res Pharm Sci. 2018;13(3):262-272.DOI: 10.4103/1735-5362.228956.

Thompson MA 2004. ArgusLab 4.0. 1. Planaria Software LLC, Seattle, WA. Available at http://www.arguslab.com.

Fernandez D, Avilés FX, Vendrell J. A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009;44(8):3266-3271.DOI: 10.1016/j.ejmech.2009.03.034.

Burley SK, Berman HM, Bhikadiya C, Bi C, Chen L, Di Costanzo L, et al. RCSB protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy. Nucleic Acids Res. 2019;47(D1):D464-D474.DOI: 10.1093/nar/gky1004.

Pripp AH. Docking and virtual screening of ACE inhibitory dipeptides. Eur Food Res Technol. 2007;225:589-592.DOI: 10.1007/s00217-006-0450-6.

Ellman GL, Courtney KD, Andres Jr V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88-95.DOI: 10.1016/0006-2952(61)90145-9.

ahmani-Khajouei M, Mohammadi-Farani A, Ghorbani H, Aliabadi A. Synthesis and acetylcholinesterase inhibitory assessment of 3-(2-(4-benzoylpiperazin-1-yl) ethylimino) indolin-2-one derivatives with potential anti-alzheimer effects. J Rep Pharm Sci. 2015;4(2):162-171.DOI: 10.4103/2322-1232.222583.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.DOI: 10.1006/abio.1976.9999.

Daina A, Michielin O, Zoete VJ. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717,1-13.DOI: 10.1038/srep42717.

Ghanbarpour A, Hadizadeh F, Piri F, Rashidi-Ranjbar P. Synthesis, conformational analysis and antidepressant activity of moclobemide new analogues. Pharm Acta Helv. 1997;72(2): 119-122.DOI: 10.1016/s0031-6865(97)00004-6.

Kapuriya N, Kakadiya R, Dong H, Kumar A, Lee P, Zhang X, et al. Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents. Bioorg Med Chem. 2011;19(1):471-485.DOI: 10.1016/j.bmc.2010.11.005.

Hassanzadeh M, Hassanzadeh F, Khodarahmi GA, Rostami M, Azimi F, Nadri H, et al. Design, synthesis, and bio-evaluation of new isoindoline-1,3-dione derivatives as possible inhibitors of acetylcholinesterase. Res Pharm Sci. 2021;16(5): 482-492.DOI: 10.4103/1735-5362.323915.

Drozdowska D, Maliszewski D, Wróbel A, Ratkiewicz A, Sienkiewicz M. New benzamides as multi-targeted compounds: a study on synthesis, AChE and BACE1 inhibitory activity and molecular docking. Int J Mol Sci. 2023;24(19):14901,1-18.DOI: 10.3390/ijms241914901.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.